Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia.
To determine the maximal tolerable dosage of trimetrexate for treatment of pneumocystis pneumonia, 25 patients were treated each day with 45 mg/m2 of trimetrexate and 80 mg/m2 of leucovorin; 10 received 60 mg/m2 and 80 mg/m2; 12 received 60 mg/m2 and 160 mg/m2; and 6 received 90 mg/m2 and 160 mg/m2, respectively. Leucovorin was increased twofold and trimetrexate reduced by 50% or suspended briefly for various levels of neutropenia and thrombocytopenia until blood counts increased. Dosage-modifying hematologic toxicity occurred in 12 (46%), 8 (80%), 9 (75%), and 4 (67%) patients with the respective groups. Cytopenias were in each case reversible and other toxicities were well tolerated. All survivors but one were able to receive a full 21 doses of trimetrexate. Twenty-four (92%), 10 (100%), 7 (58%), and 4 (80%) of patients in the respective groups survived. Thus, the 45 mg/m2/day dosage of trimetrexate with 80 mg/m2/day of leucovorin resulted in the least dosage-modifying toxicity and excellent efficacy. This combination should be selected for studies to compare trimetrexate with other therapies for pneumocystis pneumonia.
Sattler
F R
FR
Los Angeles County-University of Southern California Medical Center 90033.
Allegra
C J
CJ
Verdegem
T D
TD
Akil
B
B
Tuazon
C U
CU
Hughlett
C
C
Ogata-Arakaki
D
D
Feinberg
J
J
Shelhamer
J
J
Lane
H C
HC
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000209:etiology; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016597:Trimetrexate
D011799:Quinazolines; D002955:Leucovorin; D016597:Trimetrexate